Lori Wirth
MD
Associate Professor of Medicine
👥Biography 个人简介
Lori Wirth leads thyroid cancer clinical research at Massachusetts General Hospital with particular expertise in BRAF- and RET-driven thyroid cancers. She has been involved in pivotal trials of dabrafenib plus trametinib in BRAF V600E anaplastic thyroid cancer and targeted therapies for advanced differentiated disease. Her work has established BRAF/MEK inhibition as a standard approach for select thyroid cancer subtypes. She is a recognized educator and clinical trialist in endocrine oncology.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 Lori Wirth 的研究动态
Follow Lori Wirth's research updates
留下邮箱，当我们发布与 Lori Wirth（Massachusetts General Hospital, Harvard Medical School）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment